Endocrine & hormone · target hub

HSD17B12

Very-long-chain 3-oxoacyl-CoA reductase (HSD17B12)

HSD17B12 is a Steroidogenic enzyme on the endocrine & hormone axis. Catalyzes the second of the four reactions of the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of two carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. This enzyme has a 3-ketoacyl-C… It is indexed under "Steroidogenesis & steroid-metabolizing enzymes (gonadal/adrenal)" on our pathway page for antibodies, inhibitors, and assay guidance.

Back to pathway overviewSearch: HSD17B12UniProt (A0A1B0GV93)

Research notes

  • Combine with other genes in the same hub block via genetics or pharmacology to test non-redundant roles of HSD17B12.
  • For nuclear receptors pair ligands, co-regulators, and reporter assays; for membrane receptors note GPCR/RTK downstream and desensitization.
  • Verify antibody clone, phospho-site, and stimulation; include KD/KO or inhibitor controls.

On the pathway hub (sections)

Genetic lesions & expression context (quick reference)

Type / exampleDomain / context (brief)
Enzyme activityCatalytic or substrate-channel changes
Steroid outputSteroid profile / metabolite readouts
Rare variantsSporadic variants—require validation

Naming and prevalence vary by cohort and assay—annotate clinically with COSMIC, ClinVar, OncoKB, and datasheets; research context only.

Assay readouts for HSD17B12

  • Enzyme / metabolomics: steroid intermediates at the HSD17B12 step.
  • H295R / primary adrenals: ACTH or cAMP time courses.
  • Localization: mitochondrial STAR transfer or ER P450.
  • Endocrine phenotypes: cortisol/aldosterone/sex-steroid panels.

HSD17B12 experimental notes

Examples below reflect common literature and public resources (e.g., CCLE, DepMap)—validate genotypes, expression, and passage in your own stocks before committing assays.

[1] Cell lines commonly used for HSD17B12 studies (examples)

  • Tool lines: H295R, NCI-H295R, BeWo, MA-10, HEK293T—screen by HSD17B12 expression and pathway context (CCLE/DepMap).
  • Combine with neighbors (STAR, CYP11A1, CYP11B1, CYP11B2) via KD/pharmacology to test non-redundancy.
  • Overexpression/rescue in HEK293T supports mechanism and IP workflows.
  • Isogenic/CRISPR models separate pathway dependency from bypass survival.

[2] Cell samples for HSD17B12 Western blot

  • Whole-cell lysates—optimize RIPA/NP-40 per antibody; phosphatase inhibitors for phospho blots.
  • Stimulation: serum starvation ± insulin/EGF or amino-acid withdrawal/refeed as relevant.
  • Controls: siRNA/shRNA, CRISPR KO, or inhibitors to validate band specificity.
  • Loading: BCA normalization; subcellular fractionation when needed.

[3] Tissue samples for HSD17B12 Western blot

  • Matched tumor/adjacent frozen tissues after pathology review.
  • Mouse GEMM or xenografts—mind species antibody cross-reactivity.
  • Primary cells/PDCs when ethically approved.
  • FFPE needs specialized extraction; frozen tissue preferred for phospho work.

[4] Cell samples for HSD17B12 immunoprecipitation

  • Tagged overexpression: HEK293T FLAG/HA-HSD17B12 for complex capture.
  • Endogenous IP: high-expression lines; often ≥1–5×10⁶ cells per IP.
  • Stimulation: ligand or nutrient treatments enrich interactions—pilot time courses.
  • Controls: isotype IgG, empty vector, KD/KO negatives.

Human tissues and primary cells require ethics/IRB approval; tumors are heterogeneous—record histotype, site, and preservation conditions.

Bypass & related pathways

Models & genetics note

Overexpression vs endogenous HSD17B12 can differ in dosage, splicing, and compartmentation—in organoids/PDX, record passage, matrix, and drug history.

Quick search presets

HSD17B12HSD17B12 antibodyHSD17B12 ligand/agonisthormone/receptor antibody

HSD17B12-related antibodies (keyword-biased)

Adds HSD17B12 keyword bias atop the 内分泌和激素 antibody pool—if sparse, use presets above or global search.

Neighboring targets (same hub)

STARCYP11A1CYP11B1CYP11B2CYP17A1CYP19A1CYP21A2HSD3B1

External databases & resources

FAQ

This content supports research reagents and pathway education—not medical advice. Annotate mutations, drug indications, and protocols with authoritative databases, datasheets, and institutional oversight.

Last reviewed: 2026-05-18

Related on this site

See the endocrine & hormone hub for neighboring targets—cross-check PI3K, MAPK, RTK, and metabolism pages as needed.

Endocrine & hormone·PI3K/Akt/mTOR·MAPK/ERK·Receptor tyrosine kinase·Metabolism